Cargando…
Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas
BACKGROUND: The GMZ2.6c malaria vaccine candidate is a multi-stage Plasmodium falciparum chimeric protein which contains a fragment of the sexual-stage Pfs48/45-6C protein genetically fused to GMZ2, a fusion protein of GLURP and MSP-3, that has been shown to be well tolerated, safe and immunogenic i...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729018/ https://www.ncbi.nlm.nih.gov/pubmed/34983540 http://dx.doi.org/10.1186/s12936-021-04020-6 |
_version_ | 1784626851581263872 |
---|---|
author | Baptista, Barbara Oliveira de Souza, Ana Beatriz Lopes Riccio, Evelyn Kety Pratt Bianco-Junior, Cesare Totino, Paulo Renato Rivas Martins da Silva, João Hermínio Theisen, Michael Singh, Susheel Kumar Amoah, Linda Eva Ribeiro-Alves, Marcelo Souza, Rodrigo Medeiros Lima-Junior, Josué Costa Daniel-Ribeiro, Cláudio Tadeu Pratt-Riccio, Lilian Rose |
author_facet | Baptista, Barbara Oliveira de Souza, Ana Beatriz Lopes Riccio, Evelyn Kety Pratt Bianco-Junior, Cesare Totino, Paulo Renato Rivas Martins da Silva, João Hermínio Theisen, Michael Singh, Susheel Kumar Amoah, Linda Eva Ribeiro-Alves, Marcelo Souza, Rodrigo Medeiros Lima-Junior, Josué Costa Daniel-Ribeiro, Cláudio Tadeu Pratt-Riccio, Lilian Rose |
author_sort | Baptista, Barbara Oliveira |
collection | PubMed |
description | BACKGROUND: The GMZ2.6c malaria vaccine candidate is a multi-stage Plasmodium falciparum chimeric protein which contains a fragment of the sexual-stage Pfs48/45-6C protein genetically fused to GMZ2, a fusion protein of GLURP and MSP-3, that has been shown to be well tolerated, safe and immunogenic in clinical trials performed in a malaria-endemic area of Africa. However, there is no data available on the antigenicity or immunogenicity of GMZ2.6c in humans. Considering that circulating parasites can be genetically distinct in different malaria-endemic areas and that host genetic factors can influence the immune response to vaccine antigens, it is important to verify the antigenicity, immunogenicity and the possibility of associated protection in individuals living in malaria-endemic areas with different epidemiological scenarios. Herein, the profile of antibody response against GMZ2.6c and its components (MSP-3, GLURP and Pfs48/45) in residents of the Brazilian Amazon naturally exposed to malaria, in areas with different levels of transmission, was evaluated. METHODS: This study was performed using serum samples from 352 individuals from Cruzeiro do Sul and Mâncio Lima, in the state of Acre, and Guajará, in the state of Amazonas. Specific IgG, IgM, IgA and IgE antibodies and IgG subclasses were detected by Enzyme-Linked Immunosorbent Assay. RESULTS: The results showed that GMZ2.6c protein was widely recognized by naturally acquired antibodies from individuals of the Brazilian endemic areas with different levels of transmission. The higher prevalence of individuals with antibodies against GMZ2.6c when compared to its individual components may suggest an additive effect of GLURP, MSP-3, and Pfs48/45 when inserted in a same construct. Furthermore, naturally malaria-exposed individuals predominantly had IgG1 and IgG3 cytophilic anti-GMZ2.6c antibodies, an important fact considering that the acquisition of anti-malaria protective immunity results from a delicate balance between cytophilic/non-cytophilic antibodies. Interestingly, anti-GMZ2.6c antibodies seem to increase with exposure to malaria infection and may contribute to parasite immunity. CONCLUSIONS: The data showed that GMZ2.6c protein is widely recognized by naturally acquired antibodies from individuals living in malaria-endemic areas in Brazil and that these may contribute to parasite immunity. These data highlight the importance of GMZ2.6c as a candidate for an anti-malarial vaccine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-021-04020-6. |
format | Online Article Text |
id | pubmed-8729018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87290182022-01-07 Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas Baptista, Barbara Oliveira de Souza, Ana Beatriz Lopes Riccio, Evelyn Kety Pratt Bianco-Junior, Cesare Totino, Paulo Renato Rivas Martins da Silva, João Hermínio Theisen, Michael Singh, Susheel Kumar Amoah, Linda Eva Ribeiro-Alves, Marcelo Souza, Rodrigo Medeiros Lima-Junior, Josué Costa Daniel-Ribeiro, Cláudio Tadeu Pratt-Riccio, Lilian Rose Malar J Research BACKGROUND: The GMZ2.6c malaria vaccine candidate is a multi-stage Plasmodium falciparum chimeric protein which contains a fragment of the sexual-stage Pfs48/45-6C protein genetically fused to GMZ2, a fusion protein of GLURP and MSP-3, that has been shown to be well tolerated, safe and immunogenic in clinical trials performed in a malaria-endemic area of Africa. However, there is no data available on the antigenicity or immunogenicity of GMZ2.6c in humans. Considering that circulating parasites can be genetically distinct in different malaria-endemic areas and that host genetic factors can influence the immune response to vaccine antigens, it is important to verify the antigenicity, immunogenicity and the possibility of associated protection in individuals living in malaria-endemic areas with different epidemiological scenarios. Herein, the profile of antibody response against GMZ2.6c and its components (MSP-3, GLURP and Pfs48/45) in residents of the Brazilian Amazon naturally exposed to malaria, in areas with different levels of transmission, was evaluated. METHODS: This study was performed using serum samples from 352 individuals from Cruzeiro do Sul and Mâncio Lima, in the state of Acre, and Guajará, in the state of Amazonas. Specific IgG, IgM, IgA and IgE antibodies and IgG subclasses were detected by Enzyme-Linked Immunosorbent Assay. RESULTS: The results showed that GMZ2.6c protein was widely recognized by naturally acquired antibodies from individuals of the Brazilian endemic areas with different levels of transmission. The higher prevalence of individuals with antibodies against GMZ2.6c when compared to its individual components may suggest an additive effect of GLURP, MSP-3, and Pfs48/45 when inserted in a same construct. Furthermore, naturally malaria-exposed individuals predominantly had IgG1 and IgG3 cytophilic anti-GMZ2.6c antibodies, an important fact considering that the acquisition of anti-malaria protective immunity results from a delicate balance between cytophilic/non-cytophilic antibodies. Interestingly, anti-GMZ2.6c antibodies seem to increase with exposure to malaria infection and may contribute to parasite immunity. CONCLUSIONS: The data showed that GMZ2.6c protein is widely recognized by naturally acquired antibodies from individuals living in malaria-endemic areas in Brazil and that these may contribute to parasite immunity. These data highlight the importance of GMZ2.6c as a candidate for an anti-malarial vaccine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-021-04020-6. BioMed Central 2022-01-04 /pmc/articles/PMC8729018/ /pubmed/34983540 http://dx.doi.org/10.1186/s12936-021-04020-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Baptista, Barbara Oliveira de Souza, Ana Beatriz Lopes Riccio, Evelyn Kety Pratt Bianco-Junior, Cesare Totino, Paulo Renato Rivas Martins da Silva, João Hermínio Theisen, Michael Singh, Susheel Kumar Amoah, Linda Eva Ribeiro-Alves, Marcelo Souza, Rodrigo Medeiros Lima-Junior, Josué Costa Daniel-Ribeiro, Cláudio Tadeu Pratt-Riccio, Lilian Rose Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas |
title | Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas |
title_full | Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas |
title_fullStr | Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas |
title_full_unstemmed | Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas |
title_short | Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas |
title_sort | naturally acquired antibody response to a plasmodium falciparum chimeric vaccine candidate gmz2.6c and its components (msp-3, glurp, and pfs48/45) in individuals living in brazilian malaria-endemic areas |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729018/ https://www.ncbi.nlm.nih.gov/pubmed/34983540 http://dx.doi.org/10.1186/s12936-021-04020-6 |
work_keys_str_mv | AT baptistabarbaraoliveira naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT desouzaanabeatrizlopes naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT riccioevelynketypratt naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT biancojuniorcesare naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT totinopaulorenatorivas naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT martinsdasilvajoaoherminio naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT theisenmichael naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT singhsusheelkumar naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT amoahlindaeva naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT ribeiroalvesmarcelo naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT souzarodrigomedeiros naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT limajuniorjosuecosta naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT danielribeiroclaudiotadeu naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas AT prattricciolilianrose naturallyacquiredantibodyresponsetoaplasmodiumfalciparumchimericvaccinecandidategmz26canditscomponentsmsp3glurpandpfs4845inindividualslivinginbrazilianmalariaendemicareas |